Then, survival analysis showed that overall survival (OS) and disease free survival (DFS) of CRC patients with both high expression of PGRN and α-SMA were much worse than patients with both low expression of PGRN and α-SMA (p = 0.029 and 0.004, respectively; Figure 1B and 1C; Supplementary Tables 1 and 2). This evidence concerns the gene GRN and colorectal carcinoma.